Mutations in the gyrA, parC, and parE Genes Associated with Fluoroquinolone Resistance in Clinical Isolates of Mycoplasma hominis

This Article

	Full Text
	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager
	Reprints and Permissions
	Copyright Information
	Books from ASM Press
	MicrobeWorld

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Bebear, C. M.
	Articles by Bebear, C.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Bebear, C. M.
	Articles by Bebear, C.

Previous Article | Next Article

Antimicrobial Agents and Chemotherapy, April 1999, p. 954-956, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Mutations in the gyrA, parC, and parE Genes Associated with Fluoroquinolone Resistance in Clinical Isolates of Mycoplasma hominis

Cécile M. Bebear,¹^,²^,^* Joel Renaudin,² Alain Charron,¹ Hélène Renaudin,¹ Bertille de Barbeyrac,¹ Thierry Schaeverbeke,¹ and Christiane Bebear¹

Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex,¹ and Laboratoire de Biologie Cellulaire et Moléculaire, Institut National de la Recherche Agronomique, 33883 Villenave d'Ornon Cedex,² France

Received 5 October 1998/Returned for modification 25 November 1998/Accepted 25 January 1999

Five clinical isolates of Mycoplasma hominis from three different patients were examined for resistance to fluoroquinolones;some of these isolates were probably identical. All five isolatesharbored amino acid substitutions in the quinolone resistance-determiningregions of both DNA gyrase (GyrA) and topoisomerase IV (ParC orParE). Furthermore, the novobiocin MIC for three isolates showeda significant increase. This is the first characterization offluoroquinolone-resistant clinical mycoplasma isolates fromhumans.

^* Corresponding author. Mailing address: Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 146 rue LéoSaignat, 33076 Bordeaux Cedex, France. Phone: (33) 5.57.57.16.25.Fax: (33) 5.56.79.56.11. E-mail: cecile.bebear{at}u-bordeaux2.fr.

Antimicrobial Agents and Chemotherapy, April 1999, p. 954-956, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

Degrange, S., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2008). Tetracycline Resistance in Ureaplasma spp. and Mycoplasma hominis: Prevalence in Bordeaux, France, from 1999 to 2002 and Description of Two tet(M)-Positive Isolates of M. hominis Susceptible to Tetracyclines. Antimicrob. Agents Chemother. 52: 742-744 [Abstract] [Full Text]
Waites, K. B., Katz, B., Schelonka, R. L. (2005). Mycoplasmas and Ureaplasmas as Neonatal Pathogens. Clin. Microbiol. Rev. 18: 757-789 [Abstract] [Full Text]
Gruson, D., Pereyre, S., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2005). In Vitro Development of Resistance to Six and Four Fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, Respectively. Antimicrob. Agents Chemother. 49: 1190-1193 [Abstract] [Full Text]
Raherison, S., Gonzalez, P., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2005). Increased Expression of Two Multidrug Transporter-Like Genes Is Associated with Ethidium Bromide and Ciprofloxacin Resistance in Mycoplasma hominis. Antimicrob. Agents Chemother. 49: 421-424 [Abstract] [Full Text]
Vicca, J., Stakenborg, T., Maes, D., Butaye, P., Peeters, J., de Kruif, A., Haesebrouck, F. (2004). In Vitro Susceptibilities of Mycoplasma hyopneumoniae Field Isolates. Antimicrob. Agents Chemother. 48: 4470-4472 [Abstract] [Full Text]
Waites, K. B., Talkington, D. F. (2004). Mycoplasma pneumoniae and Its Role as a Human Pathogen. Clin. Microbiol. Rev. 17: 697-728 [Abstract] [Full Text]
Pereyre, S., Renaudin, H., Bebear, C., Bebear, C. M. (2004). In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas. Antimicrob. Agents Chemother. 48: 3165-3168 [Abstract] [Full Text]
Bebear, C. M., Renaudin, H., Charron, A., Clerc, M., Pereyre, S., Bebear, C. (2003). DNA Gyrase and Topoisomerase IV Mutations in Clinical Isolates of Ureaplasma spp. and Mycoplasma hominis Resistant to Fluoroquinolones. Antimicrob. Agents Chemother. 47: 3323-3325 [Abstract] [Full Text]
Gajjar, D. A., Bello, A., Ge, Z., Christopher, L., Grasela, D. M. (2003). Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects. Antimicrob. Agents Chemother. 47: 2256-2263 [Abstract] [Full Text]
Pereyre, S., Gonzalez, P., de Barbeyrac, B., Darnige, A., Renaudin, H., Charron, A., Raherison, S., Bebear, C., Bebear, C. M. (2002). Mutations in 23S rRNA Account for Intrinsic Resistance to Macrolides in Mycoplasma hominis and Mycoplasma fermentans and for Acquired Resistance to Macrolides in M. hominis. Antimicrob. Agents Chemother. 46: 3142-3150 [Abstract] [Full Text]
Valdezate, S., Vindel, A., Echeita, A., Baquero, F., Canto, R. (2002). Topoisomerase II and IV Quinolone Resistance-Determining Regions in Stenotrophomonas maltophilia Clinical Isolates with Different Levels of Quinolone Susceptibility. Antimicrob. Agents Chemother. 46: 665-671 [Abstract] [Full Text]
Raherison, S., Gonzalez, P., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2002). Evidence of Active Efflux in Resistance to Ciprofloxacin and to Ethidium Bromide by Mycoplasma hominis. Antimicrob. Agents Chemother. 46: 672-679 [Abstract] [Full Text]
Reinhardt, A. K., Bebear, C. M., Kobisch, M., Kempf, I., Gautier-Bouchardon, A. V. (2002). Characterization of Mutations in DNA Gyrase and Topoisomerase IV Involved in Quinolone Resistance of Mycoplasma gallisepticum Mutants Obtained In Vitro. Antimicrob. Agents Chemother. 46: 590-593 [Abstract] [Full Text]
Deguchi, T., Maeda, S.-I., Tamaki, M., Yoshida, T., Ishiko, H., Ito, M., Yokoi, S., Takahashi, Y., Ishihara, S. (2001). Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother 48: 742-744 [Full Text]
Kenny, G. E., Cartwright, F. D. (2001). Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrob. Agents Chemother. 45: 2604-2608 [Abstract] [Full Text]
Oh, H., El Amin, N., Davies, T., Appelbaum, P. C., Edlund, C. (2001). gyrA Mutations Associated with Quinolone Resistance in Bacteroides fragilis Group Strains. Antimicrob. Agents Chemother. 45: 1977-1981 [Abstract] [Full Text]
Bébéar, C. M., Grau, O., Charron, A., Renaudin, H., Gruson, D., Bébéar, C. (2000). Cloning and Nucleotide Sequence of the DNA Gyrase (gyrA) Gene from Mycoplasma hominis and Characterization of Quinolone-Resistant Mutants Selected In Vitro with Trovafloxacin. Antimicrob. Agents Chemother. 44: 2719-2727 [Abstract] [Full Text]
Bebear, C. M., Renaudin, H., Charron, A., Gruson, D., Lefrancois, M., Bebear, C. (2000). In Vitro Activity of Trovafloxacin Compared to Those of Five Antimicrobials against Mycoplasmas Including Mycoplasma hominis and Ureaplasma urealyticum Fluoroquinolone-Resistant Isolates That Have Been Genetically Characterized. Antimicrob. Agents Chemother. 44: 2557-2560 [Abstract] [Full Text]
Bebear, C. M., Renaudin, H., Bryskier, A., Bebear, C. (2000). Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human Mycoplasmas. Antimicrob. Agents Chemother. 44: 1980-1982 [Abstract] [Full Text]

Clin. Vaccine Immunol.	Clin. Microbiol. Rev.
J. Clin. Microbiol.	ALL ASM JOURNALS